Spruce Biosciences (NASDAQ:SPRB) Issues Earnings Results

Posted by George Bondi on Aug 13th, 2026

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($6.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.79) by ($0.89), FiscalAI reports.

Spruce Biosciences Stock Up 5.7%

Shares of SPRB stock traded up $2.67 on Thursday, hitting $49.73. The stock had a trading volume of 33,354 shares, compared to its average volume of 57,547. Spruce Biosciences has a 52-week low of $7.00 and a 52-week high of $240.00. The stock’s 50 day moving average is $48.40 and its 200-day moving average is $57.28. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.67 and a current ratio of 4.67. The firm has a market capitalization of $136.77 million, a price-to-earnings ratio of -1.36 and a beta of 3.23.

Analyst Ratings Changes

A number of analysts have weighed in on SPRB shares. Oppenheimer restated an “outperform” rating on shares of Spruce Biosciences in a report on Wednesday, May 27th. Guggenheim started coverage on shares of Spruce Biosciences in a research report on Tuesday, June 16th. They issued a “buy” rating and a $123.00 price objective on the stock. Citizens Jmp decreased their target price on shares of Spruce Biosciences from $150.00 to $144.00 and set a “market outperform” rating for the company in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Spruce Biosciences in a research note on Friday, June 5th. Finally, JonesTrading began coverage on Spruce Biosciences in a research report on Tuesday, June 9th. They set a “buy” rating and a $135.00 price target on the stock. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $161.88.

Get Our Latest Stock Analysis on SPRB

Institutional Investors Weigh In On Spruce Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Ikarian Capital LLC lifted its stake in shares of Spruce Biosciences by 810.3% in the fourth quarter. Ikarian Capital LLC now owns 121,356 shares of the company’s stock valued at $10,571,000 after buying an additional 108,024 shares during the period. Squadron Capital Management LLC acquired a new position in Spruce Biosciences in the fourth quarter valued at about $6,098,000. Wellington Management Group LLP bought a new stake in shares of Spruce Biosciences in the fourth quarter worth about $5,135,000. ADAR1 Capital Management LLC bought a new position in shares of Spruce Biosciences during the 4th quarter valued at about $5,052,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Spruce Biosciences during the 4th quarter worth approximately $4,501,000. Institutional investors and hedge funds own 91.71% of the company’s stock.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.